• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, June 30, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Management of radial scars diagnosed on core biopsy during transition to tomosynthesis

Bioengineer by Bioengineer
May 8, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at ARRS 2019 Annual Meeting

Leesburg, VA, May 8, 2019–It may be safe to follow-up pure radial scars (RSs) diagnosed on core needle biopsy (CNB) instead of surgical excision, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The study, to be presented by Dr. Ingolf Karst of Northwestern Medicine in Chicago, was conducted to determine if the greater conspicuity of findings such as architectural distortion on digital breast tomosynthesis (DBT) versus full-field digital mammography (FFDM) would increase the detection and upgrade (UG) rate of RSs, and to identify factors informing the decision to excise surgically or observe.

The retrospective study analyzed screening and diagnostic exams during a 33-month period of transition to DBT (December 2014 to August 2017) to map the frequency of RS found on CNB and their UG rates over time in monthly increments. A 12-month (December 2014 to November 2015) pretransition timeframe (TF) was compared with a 12-month TF after transition (September 2016 to August 2017) for RSs found, UG rates, and influencing factors. The study reviewed 131,918 exams in total, consisting of 115,430 screening followed by 16,488 diagnostic mammographic exams.

Analysis of the data revealed an 82.5% relative increase in the number of RSs found after transition to DBT, and a relative decrease in UG rate compared to the pretransition TF of 54.4%. There were no upgrades to invasive cancer of all 108 diagnosed radial scars. Seventy-eight of 108 RSs were pure RSs, none of which were upgraded on excision.

UG rates for RSs diagnosed on CNB decreased after transitioning from FFDM to DBT. With no upgrades to invasive cancer or ductal carcinoma in situ (DCIS) found for pure RS, results suggest it may be safe to follow-up pure RS diagnosed on CNB.

“Interdisciplinary collaboration and use of our proprietary database deepened our knowledge of imaging findings and related pathology, such as architectural distortion and radial scar, and supports us in management changes during times of technological shifts, such as transition from FFDM to DBT, to benefit our patients” Dr. Karst stated.

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/tomosynthesis-core-biopsy-radial-scar-management.aspx

Tags: Breast CancercancerHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

How a Common Probiotic Ingredient Transforms Immune Cells into Tumor-Fighting Warriors — Cancer

How a Common Probiotic Ingredient Transforms Immune Cells into Tumor-Fighting Warriors

June 30, 2026

Cracking the Code: How Cancer Evades Antibody-Drug Conjugates and New Strategies to Overcome Resistance

June 25, 2026

MSU Scientists Reveal Mechanism Behind Ovarian Cancer’s Chemotherapy Resistance and Strategies to Overcome It

June 25, 2026

Rare Mixed Liver Cancer Underscores Diagnostic and Therapeutic Challenges

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Meta-Analysis Evaluates Duchenne Muscular Dystrophy Treatments’ Safety

Magnetic Separation Enables High-Throughput Protein Domain Analysis

Brain Signals Body After Injury: Review Suggests Discarded Vesicles May Drive Repair

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.